PaxMedica, Inc.

PaxMedica, Inc. is a clinical-stage biopharmaceutical company founded in 2018, with a primary focus on Autism Spectrum Disorder (ASD). The company is dedicated to advancing innovative therapies for individuals and families impacted by neurodevelopmental disorders. Their mission is to develop groundbreaking treatments that address the unmet medical needs of those affected by ASD. With an unwavering commitment to scientific innovation, PaxMedica aims to bring meaningful advancements to the field and provide relief from the core symptoms of autism. At present, PaxMedica has received a $7.00MPost-IPO Equity investment on 20 November 2023. The company’s headquarters is in the United States. As the company continues to empower possibilities and transform lives in the neurodevelopmental solutions space, it presents an opportunity for potential investors to join their mission and contribute to transformative change in this critical area of healthcare.